Source disclosure: February 06, 2026
Tsubota Laboratory Incorporated [4890.T]
TOKYO, Feb 06 (Pulse News Wire) – Tsubota Laboratory Incorporated (4890.T) released additional comments today addressing the results of its domestic clinical trial for the violet light irradiation device “TLG-001,” aimed at slowing myopia progression. While the primary endpoint was missed, the company highlighted significant insights indicating the device's effectiveness under certain conditions, particularly among individuals with less outdoor activity.
In response to investor inquiries, the company emphasized that the trial’s design included a broad group of children, leading to mixed outcomes due to varying levels of natural light exposure. Notably, the device showed promising effects in subgroups with limited outdoor activities, suggesting potential efficacy in specific patient profiles. CEO Tsutota Kazuo noted that while the overall primary endpoint was unmet, the trial identified key factors influencing the device’s performance, providing valuable guidance for future studies.
The company plans to refine upcoming trials by selecting patients based on their outdoor activity levels and ensuring strict adherence to treatment protocols. Additionally, Tsubota Lab stated that the positive correlation between reduced outdoor time and improved outcomes supports the biological hypothesis underlying the device. The firm remains optimistic about the scientific validity of TLG-001 and its potential benefits in managing myopia progression under defined conditions.
AI-translated content. 🟢 Confidence: High See terms • Original filing